The conference highlights the theme: Novel Technologies and Innovations for treatment of Rare Diseases
Why should Attend?
We inspire scientists, researchers, executives and students from the pharmaceutical and biotech communities, associations and societies who are keen to learn more and to network in collaborative environs of rare disease drug discovery to join.
Learn more about global developments in rare diseases and orphan drugs and its advances in the therapeutic and diagnostic market.
Deliberating strategic collaborations to accelerate rare disease clinical drug development, and improve connections between drug developers and patients to consider both parties interests.
Learn more about how patient engagement by assimilating the patient perspective into the drug development process through patient advocacy, patient-centric research, and patient groups
Hear about how the regulatory landscape for drug approvals is different between countries, and why it is imperative to keep informed about the regulations and guidelines of each region
Advance knowledge of different rare diseases and their unique challenges, as well as how treatment methods can be reassigned to other rare diseases
Introducing cell and gene therapies to rare disease treatment - learn how gene therapy methods can advance the treatment of rare diseases and why it is fetching more commercially successful
Who to Attend?
RDOD 2018 is designed for representatives from pharmaceutical, biotechnology and medical device companies as well as members of the rare disease community with responsibilities in the following areas:
Directors, Board Members, Presidents, Vice Presidents, Deans and Head of the Departments
Researchers, Scientists, Faculties, Students
Rare Diseases Associations and Societies
Patient Liaisons/Patient Advocacy Liaisons
Industrial delegates from Academia and Research
Industrial professionals from biomedical companies and healthcare sectors